Clinical trial / 2010
Neither Agaricus blazei nor Ganoderma lucidum mushroom supplements showed significant anticancer effects in prostate cancer patients with biochemical failure.
In an open-label study, 51 patients with biochemical failure following radical prostatectomy for non-metastasized prostate cancer took either Senseiro (Agaricus blazei Murill extract, n=32) or Rokkaku Reishi (Ganoderma lucidum, n=15) for 6 months. Forty-seven patients completed the protocol and were assessed. No partial response (a 50% or greater decrease in serum PSA) was observed in any patient. Alteration of PSA doubling time did not correlate with serum testosterone levels, and no serious adverse effects were observed.
- Study type
- Open-label study
- Who was studied
- 51 Japanese patients with biochemical failure after radical prostatectomy (47 completed)
- What was measured
- Partial response rate (50% or more decrease in serum PSA), PSA doubling time, serum testosterone levels, and toxicity
THE PAPER
Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study.
Yoshimura K, Kamoto T, Ogawa O, Matsui S, Tsuchiya N, Tada H, Murata K, Yoshimura K, Habuchi T, Fukushima M. Int J Urol, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.